OncoMatch/Clinical Trials/NCT03274375
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
Is NCT03274375 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including IA session and Rituximab for anti-nmdar encephalitis.
Treatment: IA session · Rituximab — The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Demographics
Prior therapy
Must have received: steroids and/or intravenous immunoglobulin — first line
after first line therapy (steroids and/or IgIV) when Rituximab therapy is warranted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03274375 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received steroids and/or intravenous immunoglobulin.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify